Lenvatinib (Kisplyx®) is indicated for the treatment of adults with advanced renal cell carcinoma, in combination with pembrolizumab, as first-line treatment.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||15/08/2022|
|Rapid review completed||22/09/2022|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of lenvatinib in combination with pembrolizumab for the first-line treatment of patients with advanced RCC compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.|